I appreciate the remarks from GC but I tend to look at the data. I had to go back to find what drove me to dive into the 2005 patent landscape. Here is the link:
"Shikonin is known for its anti-viral, anti-microbial and anti-cancer properties, while clinical trials on its anti-cancer properties continues to be performed. In fact, there is a patent established in 2005 on the anti-viral properties of Shikonin. A test performed during the SARS epidemic showed that Shikonin reduced the course of SARS from 11 to 6 days and that it has anti-viral significant properties. Dr. Dorit Arad's team at eXegenics in 2001 found that Shikonin has molecular activity against several viruses, particularly the 3C-target viral protease enzyme, and it was detected as the most active compound among the 300,000 compounds studied in this study. Gromwell Root, which contains 30% Shikonin, is regulated in Israel as a safe herbal supplement with a therapeutic index> 100 for concentrations up to 20mg per Kg."
The clinical results on SARS were positive and I expect the C19 results to be similar. GC probably wants to avoid opening a can of worms. It is a supplement but the scientist are obviously convinced that it has anti-viral properties, eh? Kudos for this presentation by the way. It is excellent and hits the nail on the head. I have sent it to friends and family.
Market Data 
Markets 
AI
